tetano
Editor, Senior Moderator
J Med Virol
. 2025 Mar;97(3):e70289.
doi: 10.1002/jmv.70289. Metabolomic Biomarkers of Pulmonary Fibrosis in COVID-19 Patients One Year After Hospital Discharge
Marina Botello-Marabotto[SUP] 1 2 3 [/SUP], Julia Tarrasó[SUP] 4 [/SUP], Alba Mulet[SUP] 4 [/SUP], Lucía Presa-Fernández[SUP] 4 [/SUP], Estrella Fernández-Fabrellas[SUP] 5 [/SUP], José A Rodríguez Portal[SUP] 6 [/SUP], Jose A Ros[SUP] 7 [/SUP], Desiré Lozano-Vicente[SUP] 8 [/SUP], Andrea Bernardos[SUP] 2 3 9 10 [/SUP], M Carmen Martínez-Bisbal[SUP] 1 2 3 11 [/SUP], Ramón Martínez-Máñez[SUP] 1 2 3 9 10 [/SUP], Jaime Signes-Costa[SUP] 4 [/SUP]
Affiliations
Coronavirus disease 2019 (COVID-19) global pandemic has affected more than 600 million people up to date. The symptomatology and severity of COVID-19 are very broad, and there are still concerns about the long-term sequelae that it can have on discharged patients. The development of pulmonary fibrotic sequelae after this infection is especially worrying. Our aim was to determine if there was a metabolomic signature that could predict the development of pulmonary fibrotic sequelae. It is a multicenter prospective observation subcohort based on the COVID-FIBROTIC study. A metabolomic analysis was performed by nuclear magnetic resonance (NMR) on serum samples from patients admitted with bilateral COVID-19 pneumonia collected 2 months after hospital discharge. One year after admission, clinical, functional and radiological data were collected from these same patients. Finally, 109 patients (mean age 57.68 [DS14.03], 65.13% male) were available. Fibrotic sequelae 1 year after COVID-19 disease were found in 33% of them. Based on the NMR analysis of the serum samples, it was possible to distinguish with 80.82% of sensitivity, 72.22% of specificity and 0.83 of an area under the curve (AUC) value which patients would have radiological signs of pulmonary fibrotic pattern 1 year after sample collection. According to the metabolites participating in the discriminative model and the univariate statistics, glucose, valine, and fatty acids (═CH-CH2-CH═) were suggested as potential biomarkers of the development of pulmonary fibrotic sequelae after COVID-19. TRIAL REGISTRATION NUMBER: clinicaltrials.gov NCT04409275 (June 1, 2020).
Keywords: 1H‐NMR spectroscopy; COVID‐19; biomarkers; metabolomics; pulmonary fibrosis.
. 2025 Mar;97(3):e70289.
doi: 10.1002/jmv.70289. Metabolomic Biomarkers of Pulmonary Fibrosis in COVID-19 Patients One Year After Hospital Discharge
Marina Botello-Marabotto[SUP] 1 2 3 [/SUP], Julia Tarrasó[SUP] 4 [/SUP], Alba Mulet[SUP] 4 [/SUP], Lucía Presa-Fernández[SUP] 4 [/SUP], Estrella Fernández-Fabrellas[SUP] 5 [/SUP], José A Rodríguez Portal[SUP] 6 [/SUP], Jose A Ros[SUP] 7 [/SUP], Desiré Lozano-Vicente[SUP] 8 [/SUP], Andrea Bernardos[SUP] 2 3 9 10 [/SUP], M Carmen Martínez-Bisbal[SUP] 1 2 3 11 [/SUP], Ramón Martínez-Máñez[SUP] 1 2 3 9 10 [/SUP], Jaime Signes-Costa[SUP] 4 [/SUP]
Affiliations
- PMID: 40088077
- DOI: 10.1002/jmv.70289
Coronavirus disease 2019 (COVID-19) global pandemic has affected more than 600 million people up to date. The symptomatology and severity of COVID-19 are very broad, and there are still concerns about the long-term sequelae that it can have on discharged patients. The development of pulmonary fibrotic sequelae after this infection is especially worrying. Our aim was to determine if there was a metabolomic signature that could predict the development of pulmonary fibrotic sequelae. It is a multicenter prospective observation subcohort based on the COVID-FIBROTIC study. A metabolomic analysis was performed by nuclear magnetic resonance (NMR) on serum samples from patients admitted with bilateral COVID-19 pneumonia collected 2 months after hospital discharge. One year after admission, clinical, functional and radiological data were collected from these same patients. Finally, 109 patients (mean age 57.68 [DS14.03], 65.13% male) were available. Fibrotic sequelae 1 year after COVID-19 disease were found in 33% of them. Based on the NMR analysis of the serum samples, it was possible to distinguish with 80.82% of sensitivity, 72.22% of specificity and 0.83 of an area under the curve (AUC) value which patients would have radiological signs of pulmonary fibrotic pattern 1 year after sample collection. According to the metabolites participating in the discriminative model and the univariate statistics, glucose, valine, and fatty acids (═CH-CH2-CH═) were suggested as potential biomarkers of the development of pulmonary fibrotic sequelae after COVID-19. TRIAL REGISTRATION NUMBER: clinicaltrials.gov NCT04409275 (June 1, 2020).
Keywords: 1H‐NMR spectroscopy; COVID‐19; biomarkers; metabolomics; pulmonary fibrosis.